No registrations found.
ID
Source
Brief title
Health condition
Myocardial infarction
Hartinfarct
Sponsors and support
Intervention
Outcome measures
Primary outcome
• Echocardiographic and enzymatic infarct size
• Microvascular obstruction and haemorrhage on MRI measurements
Secondary outcome
• Practicality / feasibility problems during imaging
• Other adverse events
• Other Serious adverse events
• Incidence of Major Adverse Cardiac Events (MACE)
Background summary
Currently, primary percutaneous coronary intervention (PCI) is the treatment of choice in STEMI patients, however, its widespread use is hampered by limited availability of specialized facilities and trained staff. Also, peripheral microvascular obstruction often occurs, as part of the microvascular injury pathway. Therefore, there is a need for simpler and low-risk methods for effective recanalization of thrombosed arteries that can be initiated early in the disease process and after initial primary PCI treatment.
In this respect, the application of ultrasound, and ultrasound in combination with thrombolytic agents have been investigated and were found to enhance thrombus dissolution in vitro and in vivo.
We hypothesize that under influence of ultrasound, UCAs enhance dissolution of thrombus in patients with acute ST-elevation myocardial infarction premedicated with regular treatment with prasugrel, aspirin and heparin followed by bivalirudin and furthermore reduce the amount of microvascular obstruction that occurs after primary PCI.
Study objective
Is application of diagnostic ultrasound and microbubbles prior and immediately after primary PCI to enhance coronary recanalization and reduce microvascular obstruction when combined with normal care consisting of prasugrel, aspirin and heparin followed by bivalirudin a safe and feasible method in this patient group?
Study design
First visit. 6 week follow-up. 6 month follow-up.
Intervention
Patients will be announced by the ambulance. After announcement by the ambulance of a patient with an eligible STEMI the patient will be pre-treated in the ambulance with a loading dose of aspirin 500 mg iv., heparin 5000 IU iv., prasugrel 60mg po.
Upon arrival on the cathlab, after oral informed consent the patient will also receive Definity Microbubbles as part of the immediate ultrasound therapy
To avoid any time delay, informed consent will be obtained orally, prior to primary PCI and bivalirudin infusion. Investigator will try to obtain written informed consent prior to study procedures. In any other case, written informed consent will be given after primary PCI when the patient is in a stable clinical condition.
After informed consent, patients will be treated with ultrasound application with an UCA. To prevent delay of intended clinical treatment, the study procedure is carried out during the preparation for primary PCI as much as possible. The whole study procedure time including preparation is expected to take a maximum of 15 minutes. After PCI, the patient will receive an additional 30 minutes of UCA treatment.
An intravenous line will be inserted, and continuous registration of a 12-lead ECG is obtained. An automatic blood pressure device will record blood pressure every three minutes during the study procedure.
VU Medisch Centrum
De Boelelaan 1117
Amsterdam 1081HV
The Netherlands
0204442244
s.roos@vumc.nl
VU Medisch Centrum
De Boelelaan 1117
Amsterdam 1081HV
The Netherlands
0204442244
s.roos@vumc.nl
Inclusion criteria
• Age > 18 years
• Acute onset (< 6 hours)
• Diagnosed with STEMI according to the criteria of the ACC
• Initial oral informed consent
Exclusion criteria
• Clinical instability
• Known allergy to ultrasound contrast agents
• Any reason judged by the investigators to hamper inclusion
Design
Recruitment
Followed up by the following (possibly more current) registration
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL4648 |
| NTR-old | NTR4791 |
| CCMO | NL46176.029.14 |
| OMON | NL-OMON41625 |
Summary results
2 Scott PA, Frederiksen SM, Kalbfleisch JD, et al. Safety of intravenous thrombolytic use in four emergency departments without acute stroke teams. Acad Emerg Med 2010 Oct;17(10):1062-71.<br>
3 Kramer C, Aguilar MI, Hoffman-Snyder C, et al. Safety and efficacy of ultrasound-enhanced thrombolysis in the treatment of acute middle cerebral artery infarction: a critically appraised topic. Neurologist 2011 Nov;17(6):346-51.<br>
4 Xie F, Lof J, Matsunaga T, et al. Diagnostic ultrasound combined with glycoprotein IIb/IIIa-targeted microbubbles improves microvascular recovery after acute coronary thrombotic occlusions. Circulation 2009 Mar 17;119(10):1378-85.<br>
5 Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996 Mar 1;93(5):879-88.<br>
6 Ndrepepa G, Tiroch K, Keta D, et al. Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction. Circ Cardiovasc Interv 2010 Feb 1;3(1):27-33.<br>
7 Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974 Dec;54(6):1496-508.<br>
8 Kondo M, Nakano A, Saito D, et al. Assessment of "microvascular no-reflow phenomenon" using technetium-99m macroaggregated albumin scintigraphy in patients with acute myocardial infarction. J Am Coll Cardiol 1998 Oct;32(4):898-903.<br>
9 Cavalcante JL, Collier P, Plana JC, et al. Two-dimensional longitudinal strain assessment in the presence of myocardial contrast agents is only feasible with speckle-tracking after microbubble destruction. J Am Soc Echocardiogr 2012 Dec;25(12):1309-18.<br>
10 Slikkerveer J, Kleijn SA, Appelman Y, et al. Ultrasound Enhanced Prehospital Thrombolysis Using Microbubbles Infusion in Patients with Acute ST Elevation Myocardial Infarction: Pilot of the Sonolysis Study. Ultrasound Med Biol 2011 Dec 16.